Last checked at 21 Oct 2016 07:43
MaxCyte, Inc.
("MaxCyte" or the "Company")
Driector/PDMR Sharedealing
Maryland, USA - 21 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines, products and services, announces that it was notified on 20 October 2016 of the following transactions:
· On 19 October 2016, John Johnston, a Non-Executive Director of the Company, purchased 37,500 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") at a price of 96 pence per share; and
· On 20 October 2016, Mr Johnston, purchased 37,500 Ordinary Shares at a price of 98 pence per share, the ("Transactions").
Following the Transactions, Mr Johnston's total beneficial interest in the Company is 75,000 Ordinary Shares, representing approximately 0.17 per cent. of the current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | John Johnston | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | MaxCyte, Inc. | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
MXCT / US57777K1060 | |
b) | Nature of the transaction | Purchase of shares | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
0.98 | 37500 | ||
0.96 | 37500 | ||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
75000 0.97 £72,750 | |
f) | Date of the transaction | 19/10/16 20/10/16
| |
g) | Place of the transaction | London Stock Exchange, AIM | |
- ENDS -
For further information please contact:
MaxCyte | +1 301 944 1660 |
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | |
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Duncan Monteith Tom Salvesen (Corporate Broking) | +44 (0) 20 7886 2500
|
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
Mary-Jane Elliott Chris Welsh Lindsey Neville |
About MaxCyte
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/